Vaccines against PCV2 [8,9] and M. hyopneumoniae [10,11] are
routinely used in the pig industry, and it has been shown that concurrent
vaccination with PCV2 and M. hyopneumoniae vaccines can
provide protection against both pathogens under laboratory conditions
[12]. However, for the convenience of the user and to reduce
the number of injections given to piglets, a ready-to-use combination
product, preferably given as a one dose regimen, would be
highly desirable. Therefore, the objective of the present studies
was to evaluate the efficacy and safety of a new ready-to-use combination
product based on the M. hyopneumoniae monovalent vaccine
M+PAC (MSD Animal Health) and the PCV vaccine Porcilis
PCV (MSD Animal Health) under laboratory and field conditions.